Qualigen Therapeutics is a clinical-stage therapeutics company dedicated to developing groundbreaking treatments for both adult and pediatric cancer. With a strong focus on science and innovation, Qualigen aims to bring about positive change in the field of healthcare. Their mission is to create treatments that instill hope and ultimately lead to improved outcomes for patients.

At the forefront of their research is the investigational QN-302 compound, a selective transcription inhibitor that targets G4s prevalent in cancer cells. By stabilizing these G4s, Qualigen aims to inhibit cancer cell proliferation. Additionally, Qualigen's family of Pan-RAS oncogene protein-protein interaction inhibitors have shown potential in blocking the harmful effects of mutated RAS genes, making them a promising option for the treatment of certain forms of pancreatic, colorectal, and lung cancers.

Another noteworthy compound is QN-247, an inhibitor of nucleolin, a protein that is commonly overexpressed in cancer cells. This compound has displayed promise in preclinical studies for the treatment of acute myeloid leukemia (AML). Driven by their unwavering commitment to patients and their families, Qualigen Therapeutics places care at the core of everything they do.

As they continue their mission, they strive to enable patients to have healthier tomorrows